CLAIMS:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 represents -C_{3-7} cycloalkyl optionally substituted by C_{1-3} alkyl;

R^2 represents hydrogen, -C_{1-6} alkyl, -C_{3-8} cycloalkyl, -C_{1-6} alkyl-C_{3-8} cycloalkyl, -aryl, -heterocyclyl, -heteroaryl, -C_{3-8} cycloalkyl-Y-C_{3-8} cycloalkyl, -C_{3-8} cycloalkyl-Y-aryl, -C_{3-8} cycloalkyl-Y-heteroaryl, -C_{3-8} cycloalkyl-Y-heterocyclyl, -aryl-Y-C_{3-8} cycloalkyl, -aryl-Y-aryl, -aryl-Y-heteroaryl, -aryl-Y-heterocyclyl, -heteroaryl-Y-C_{3-8} cycloalkyl, -heteroaryl-Y-aryl, -heteroaryl-Y-heteroaryl, -heteroaryl-Y-heterocyclyl, -heterocyclyl-Y-C_{3-8} cycloalkyl, -heterocyclyl-Y-aryl, -heterocyclyl-Y-heteroaryl, -heterocyclyl-Y-heterocyclyl;

X represents a bond, CO, SO_2, $CONR^5$, COO or COC_{2-6} alkenyl;

Y represents a bond, C_{1-6} alkyl, CO, CONH, NHCO, O, SO_2, SO_2NH or $NHSO_2$;

R^3 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;

R^4 and R^5 independently represent hydrogen, -C_{1-6} alkyl, -C_{3-8} cycloalkyl, -aryl, -heterocyclyl or –heteroaryl;

n is 0, 1 or 2;

wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R^2, R^3 and R^4 may be optionally substituted by one or more substituents (e.g. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, =O, haloC_{1-6} alkyl, haloC_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido, C_{1-6} alkylamino, C_{1-6} alkylamido, -R^8, -CO_2R^8, -COR^8, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aryl, aroyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group $–NR^6R^7$, –C_{1-6} alkyl-NR^6R^7, –C_{3-8} cycloalkyl-NR^6R^7, -$CONR^6R^7$, -NR^6COR^7, -$NR^6SO_2R^7$, -$OCONR^6R^7$, -$NR^6CO_2R^7$, -$NR^8CONR^6R^7$ or -$SO_2NR^6R^7$ (wherein R^6, R^7 and R^8 independently represent hydrogen, C_{1-6} alkyl, -C_{3-8} cycloalkyl, -C_{1-6} alkyl-C_{3-8} cycloalkyl, aryl, heterocyclyl or heteroaryl or $–NR^6R^7$ may represent a nitrogen containing heterocyclyl group, wherein said R^5, R^6 and R^7 groups may be optionally substituted by one or more substituents (e.g. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino, =O or trifluoromethyl);

or solvates thereof.

2. A compound according to claim 1 which is a compound of formula E1-E280 or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition which comprises the compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

4. A compound as defined in claim 1 or claim 2 for use in therapy.

5. A compound as defined in claim 1 or claim 2 for use in the treatment of neurological diseases.

6. Use of a compound as defined in claim 1 or claim 2 in the manufacture of a medicament for the treatment of neurological diseases.

7. A method of treatment of neurological diseases which comprises administering to a host in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition for use in the treatment of neurological diseases which comprises the compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

AMENDED CLAIMS
[received by the International Bureau on 2 June 2005 (02.06.2005);
original claim 1 amended; remaining claims unchanged (1 page)]

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:
R^1 represents -C_{3-7} cycloalkyl optionally substituted by C_{1-3} alkyl;
R^2 represents hydrogen, -C_{1-6} alkyl, -C_{3-8} cycloalkyl, -C_{1-6} alkyl-C_{3-8} cycloalkyl, -aryl, -heterocyclyl, -heteroaryl, -C_{3-8} cycloalkyl-Y-C_{3-8} cycloalkyl, -C_{3-8} cycloalkyl-Y-aryl, -C_{3-8} cycloalkyl-Y-heteroaryl, -C_{3-8} cycloalkyl-Y-heterocyclyl, -aryl-Y-C_{3-8} cycloalkyl, -aryl-Y-aryl, -aryl-Y-heteroaryl, -aryl-Y-heterocyclyl, -heteroaryl-Y-C_{3-8} cycloalkyl, -heteroaryl-Y-aryl, -heteroaryl-Y-heteroaryl, -heteroaryl-Y-heterocyclyl, -heterocyclyl-Y-C_{3-8} cycloalkyl, -heterocyclyl-Y-aryl, -heterocyclyl-Y-heteroaryl, -heterocyclyl-Y-heterocyclyl;
X represents a bond, CO, SO_2, $CONR^5$, COO or COC_{2-6} alkenyl;
Y represents a bond, C_{1-6} alkyl, CO, CONH, NHCO, O, SO_2, SO_2NH or $NHSO_2$;
R^3 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;
R^4 and R^5 independently represent hydrogen, -C_{1-6} alkyl, -C_{3-8} cycloalkyl, -aryl, -heterocyclyl or -heteroaryl;
n is 0, 1 or 2;
wherein said alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R^2, R^3 and R^4 may be optionally substituted by one or more substituents (e.g. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, =O, haloC_{1-6} alkyl, haloC_{1-6} alkoxy, C_{1-6} alkyl, C_{1-6} alkoxy, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido, C_{1-6} alkylamino, C_{1-6} alkylamido, -R^8, -CO_2R^8, -COR^8, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aryl, aroyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group $-NR^6R^7$, -C_{1-6} alkyl-NR^6R^7, -C_{3-8} cycloalkyl-NR^6R^7, -$CONR^6R^7$, -NR^6COR^7, -$NR^6SO_2R^7$, -$OCONR^6R^7$, -$NR^6CO_2R^7$, -$NR^8CONR^6R^7$ or -$SO_2NR^6R^7$ (wherein R^6, R^7 and R^8 independently represent hydrogen, C_{1-6} alkyl, -C_{3-8} cycloalkyl, -C_{1-6} alkyl-C_{3-8} cycloalkyl, aryl, heterocyclyl or heteroaryl or $-NR^6R^7$ may represent a nitrogen containing heterocyclyl group, wherein said R^5, R^6 and R^7 groups may be optionally substituted by one or more substituents (e.g. 1, 2 or 3) which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino, =O or trifluoromethyl);
or solvates thereof;
wherein said compound is not 7-amino-3-cyclopropyl-2,3,4,5-tetrahydro-1H-3-benzazepine.